Seladelpar

Seladelpar is used to treat primary biliary cholangitis in adults a chronic autoimmune liver disease characterized by progressive damage to the bile ducts. It is a selective peroxisome proliferator activated receptor delta(PPARδ) agonist that aims to reduce liver inflammation, received approval from the U.S. FDA in August 2024.

BRAND NAME:

Livdelzi – It is available in the form of oral tablets with strength seladelpar 10mg.

MECHANISM OF ACTION:

Seladelpar selectively binds to and activates PPARδ one of the three PPAR nuclear receptors(α, β/δ, and γ). PPARδ is a transcription factor that regulates the expression of genes involved in lipid metabolism, inflammation, and bile acid homeostasis. Activation of PPARδ leads to downregulation of pro-inflammatory cytokines and reduction of immune cell activity in the liver. This helps reduce inflammation and protect cholangiocytes (bile duct cells) from immune-mediated damage, which is central to PBC. PPARδ activation modulates genes involved in bile acid metabolism, such as CYP7A1, reducing bile acid production. This helps reduce bile acid toxicity, a major contributor to liver damage in PBC. Seladelpar enhances the expression of transporters involved in bile acid excretion, which aids in clearing accumulated bile acids from the liver.